Nuclear α-actinin-4 regulates breast cancer invasiveness and EMT

被引:0
|
作者
Saha, Sumon Kumar [1 ]
Sarkar, Madhurima [1 ]
Srivastava, Mahima [2 ]
Dutta, Sarbajeet [1 ]
Sen, Shamik [1 ]
机构
[1] Indian Inst Technol, Dept Biosci & Bioengn, Mumbai, India
[2] Vellore Inst Technol, Vellore, India
关键词
ACTN4; EMT; invasiveness; K255E; TGF beta; ALPHA-ACTININ; 4; MESENCHYMAL TRANSITION; MOLECULAR-MECHANISMS; CELL MOTILITY; GROWTH; NETWORKS; DYNAMICS; ENHANCER; REVEALS; SNAIL;
D O I
10.1002/cm.21901
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Epithelial-to-mesenchymal transition (EMT) is a key process where cells lose their adhesion properties and augment their invasive properties. alpha-Actinin4 (ACTN4) is an actin crosslinking protein that responds to mechanical stimuli and is found to be elevated in breast cancer patients. While ACTN4 has been implicated in regulating cancer invasiveness by modulating cytoskeletal organization, its nuclear functions remain much less explored. Here we address this question by first establishing a correlation between nuclear localization and invasiveness in breast cancer cells. Using cancer databases, we then establish a correlation between ACTN4 expression and EMT in breast cancer. Interestingly, TGF beta-induced EMT induction in MCF10A normal mammary epithelial cells leads to increased ACTN4 expression and nuclear enrichment. We then show that ACTN4 knockdown in MDA-MB-231 breast cancer cells, which harbor sizeable fraction of nuclear ACTN4, leads to reduced invasiveness and loss of mesenchymal traits. Similar behavior was observed in knockdown cells expressing K255E ACTN4, which is primarily localized to the cytosol. Together, our findings establish a role for nuclear ACTN4 in regulating invasiveness via modulation of EMT.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] α-Actinin-4 confers radioresistance coupled invasiveness in breast cancer cells through AKT pathway
    Desai, Sejal
    Barai, Amlan
    Bukhari, Amirali B.
    De, Abhijit
    Sen, Shamik
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2018, 1865 (01): : 196 - 208
  • [2] Actinin-4 as a Diagnostic Biomarker in Serum of Breast Cancer Patients
    Fang, Cheng
    Li, Juan-Juan
    Deng, Tong
    Li, Bing-Hui
    Geng, Pei-Liang
    Zeng, Xian-Tao
    MEDICAL SCIENCE MONITOR, 2019, 25 : 3298 - 3302
  • [3] α-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer
    Jung, Jaeyeon
    Kim, Suhyun
    An, Hyoung-Tae
    Ko, Jesang
    CARCINOGENESIS, 2020, 41 (07) : 940 - 949
  • [4] Increased expression of α-actinin-4 is associated with unfavorable pathological features and invasiveness of bladder cancer
    Yoshii, Hidehiko
    Ito, Keiichi
    Asano, Takako
    Horiguchi, Akio
    Hayakawa, Masamichi
    Asano, Tomohiko
    ONCOLOGY REPORTS, 2013, 30 (03) : 1073 - 1080
  • [5] α-Actinin-4 Is Required for Amoeboid-type Invasiveness of Melanoma Cells
    Shao, Hanshuang
    Li, Shaoyan
    Watkins, Simon C.
    Wells, Alan
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (47) : 32717 - 32728
  • [6] The Role of Actinin-4 in Bladder Cancer Invasion
    Koizumi, Takahiro
    Nakatsuji, Hiroyoshi
    Fukawa, Tomoya
    Avirmed, Shiirevnyamba
    Fukumori, Tomoharu
    Takahashi, Masayuki
    Kanayama, Hiroomi
    UROLOGY, 2010, 75 (02) : 357 - 364
  • [7] α-Actinin-4 promotes metastasis in gastric cancer
    Liu, Xin
    Chu, Kent-Man
    LABORATORY INVESTIGATION, 2017, 97 (09) : 1084 - 1094
  • [8] The biological role of actinin-4 for cancer invasion and metastasis
    Honda, Kazufumi
    Yamada, Tesshi
    SEIKAGAKU, 2007, 79 (07): : 643 - 654
  • [9] α-Actinin-4 drives invasiveness by regulating myosin IIB expression and myosin IIA localization
    Barai, Amlan
    Mukherjee, Abhishek
    Das, Alakesh
    Saxena, Neha
    Sen, Shamik
    JOURNAL OF CELL SCIENCE, 2021, 134 (23)
  • [10] E-cadherin regulates the association between β-catenin and actinin-4
    Hayashida, Y
    Honda, K
    Idogawa, M
    Ino, Y
    Ono, M
    Tsuchida, A
    Aoki, T
    Hirohashi, S
    Yamada, T
    CANCER RESEARCH, 2005, 65 (19) : 8836 - 8845